We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Hims & Hers Health, Inc. (HIMS) Rises Higher Than Market: Key Facts
Read MoreHide Full Article
Hims & Hers Health, Inc. (HIMS - Free Report) closed the most recent trading day at $35.45, moving +2.12% from the previous trading session. The stock outpaced the S&P 500's daily gain of 0.62%. At the same time, the Dow added 0.99%, and the tech-heavy Nasdaq gained 0.65%.
The company's shares have seen a decrease of 11.27% over the last month, not keeping up with the Medical sector's loss of 1.22% and the S&P 500's gain of 0.59%.
The upcoming earnings release of Hims & Hers Health, Inc. will be of great interest to investors. On that day, Hims & Hers Health, Inc. is projected to report earnings of $0.04 per share, which would represent a year-over-year decline of 63.64%. In the meantime, our current consensus estimate forecasts the revenue to be $620.41 million, indicating a 28.94% growth compared to the corresponding quarter of the prior year.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $0.48 per share and a revenue of $2.35 billion, representing changes of +77.78% and 0%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for Hims & Hers Health, Inc. Such recent modifications usually signify the changing landscape of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Hims & Hers Health, Inc. is currently sporting a Zacks Rank of #4 (Sell).
In terms of valuation, Hims & Hers Health, Inc. is currently trading at a Forward P/E ratio of 58.81. This signifies a premium in comparison to the average Forward P/E of 28 for its industry.
We can additionally observe that HIMS currently boasts a PEG ratio of 5.62. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical Info Systems industry currently had an average PEG ratio of 2.24 as of yesterday's close.
The Medical Info Systems industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 180, which puts it in the bottom 27% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Hims & Hers Health, Inc. (HIMS) Rises Higher Than Market: Key Facts
Hims & Hers Health, Inc. (HIMS - Free Report) closed the most recent trading day at $35.45, moving +2.12% from the previous trading session. The stock outpaced the S&P 500's daily gain of 0.62%. At the same time, the Dow added 0.99%, and the tech-heavy Nasdaq gained 0.65%.
The company's shares have seen a decrease of 11.27% over the last month, not keeping up with the Medical sector's loss of 1.22% and the S&P 500's gain of 0.59%.
The upcoming earnings release of Hims & Hers Health, Inc. will be of great interest to investors. On that day, Hims & Hers Health, Inc. is projected to report earnings of $0.04 per share, which would represent a year-over-year decline of 63.64%. In the meantime, our current consensus estimate forecasts the revenue to be $620.41 million, indicating a 28.94% growth compared to the corresponding quarter of the prior year.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $0.48 per share and a revenue of $2.35 billion, representing changes of +77.78% and 0%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for Hims & Hers Health, Inc. Such recent modifications usually signify the changing landscape of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Hims & Hers Health, Inc. is currently sporting a Zacks Rank of #4 (Sell).
In terms of valuation, Hims & Hers Health, Inc. is currently trading at a Forward P/E ratio of 58.81. This signifies a premium in comparison to the average Forward P/E of 28 for its industry.
We can additionally observe that HIMS currently boasts a PEG ratio of 5.62. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical Info Systems industry currently had an average PEG ratio of 2.24 as of yesterday's close.
The Medical Info Systems industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 180, which puts it in the bottom 27% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.